Pacific Biosciences Of California (PACB) Total Non-Current Liabilities (2012 - 2026)
Pacific Biosciences Of California's quarterly Total Non-Current Liabilities came in at $772.0 million in Q1 2026, little changed year-on-year from $769.2 million in Q1 2025, and down 0.86% quarter-over-quarter from $778.7 million in Q4 2025.
Pacific Biosciences Of California has reported Total Non-Current Liabilities for 14 years, with the latest figure at $772.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.37% year-over-year to $772.0 million; the trailing twelve-month figure through Mar 2026 stood at $772.0 million (changed 0.37% YoY), and the FY2025 full-year result was $778.7 million, up 3.38% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $772.0 million, down from $778.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.2 billion in Q4 2022, with the low at $753.3 million in Q4 2024.
- Average Total Non-Current Liabilities over 5 years is $947.5 million, with a median of $1.0 billion recorded in 2023.
- Year-over-year, Total Non-Current Liabilities soared 612.43% in 2022 and dropped 26.52% in 2024.
- Tracing PACB's Total Non-Current Liabilities over 5 years: stood at $1.2 billion in 2022, then retreated by 14.77% to $1.0 billion in 2023, then slipped by 26.52% to $753.3 million in 2024, then rose by 3.38% to $778.7 million in 2025, then retreated by 0.86% to $772.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $772.0 million (Q1 2026), $778.7 million (Q4 2025), and $767.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 2.44 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 3.53 Bn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 3.47 Bn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | 772.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 772.00 Mn |
| Dec 31, 2025 | 778.73 Mn |
| Sep 30, 2025 | 767.07 Mn |
| Jun 30, 2025 | 763.98 Mn |
| Mar 31, 2025 | 769.15 Mn |
| Dec 31, 2024 | 753.31 Mn |
| Sep 30, 2024 | 996.18 Mn |
| Jun 30, 2024 | 997.31 Mn |
| Mar 31, 2024 | 1.02 Bn |
| Dec 31, 2023 | 1.03 Bn |
| Sep 30, 2023 | 1.13 Bn |
| Jun 30, 2023 | 1.02 Bn |
| Mar 31, 2023 | 1.02 Bn |
| Dec 31, 2022 | 1.20 Bn |
| Sep 30, 2022 | 1.02 Bn |
| Jun 30, 2022 | 1.03 Bn |
| Mar 31, 2022 | 1.03 Bn |
| Dec 31, 2021 | 1.05 Bn |
| Sep 20, 2021 | -200.00 Mn |
| Jun 30, 2021 | 986.78 Mn |
| Mar 31, 2021 | 971.58 Mn |
| Dec 31, 2020 | 77.74 Mn |
| Dec 31, 2018 | 56.20 Mn |
| Sep 30, 2018 | 51.00 Mn |
| Jun 30, 2018 | 51.54 Mn |
| Mar 31, 2018 | 54.20 Mn |
| Dec 31, 2017 | 57.80 Mn |
| Sep 30, 2017 | 56.33 Mn |
| Jun 30, 2017 | 62.03 Mn |
| Mar 31, 2017 | 66.12 Mn |
| Dec 31, 2016 | 52.86 Mn |
| Sep 30, 2016 | 51.74 Mn |
| Jun 30, 2016 | 51.77 Mn |
| Mar 31, 2016 | 50.85 Mn |
| Dec 31, 2015 | 56.18 Mn |
| Sep 30, 2015 | 57.08 Mn |
| Jun 30, 2015 | 60.74 Mn |
| Mar 31, 2015 | 65.09 Mn |
| Dec 31, 2014 | 68.50 Mn |
| Sep 30, 2014 | 67.91 Mn |
| Jun 30, 2014 | 68.53 Mn |
| Mar 31, 2014 | 64.97 Mn |
| Dec 31, 2013 | 66.46 Mn |
| Sep 30, 2013 | 68.36 Mn |
| Jun 30, 2013 | 32.99 Mn |
| Dec 31, 2012 | 18.16 Mn |